8-KEarnings & ResultsExhibits & Filings

REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Nov 4, 2009)

Filed November 4, 2009For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed a Form 8-K on November 4, 2009, primarily to report its financial and operating results for the quarter ended September 30, 2009. This filing incorporates a press release issued on November 3, 2009, which would contain the detailed financial performance and operational updates for the period. Investors should refer to the attached press release (Exhibit 99.1) for specifics on revenue, earnings, pipeline progress, and any significant business developments that occurred during the third quarter of 2009. The significance of this filing lies in its provision of timely financial data and operational insights, allowing investors to assess Regeneron's performance against expectations and its peers. Key metrics likely discussed in the press release include net income, revenue growth, and updates on clinical trials and drug development programs, which are critical for evaluating the company's trajectory and future prospects.

Key Highlights

  • 1Regeneron Pharmaceuticals (REGN) filed an 8-K on November 4, 2009, to report Q3 2009 financial and operating results.
  • 2The report includes a press release dated November 3, 2009, as Exhibit 99.1.
  • 3This press release contains the company's financial and operational performance for the quarter ended September 30, 2009.
  • 4Investors can find detailed financial performance metrics and business updates in the furnished press release.
  • 5The filing adheres to Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Financial Statements and Exhibits) of Form 8-K.

Frequently Asked Questions

The primary purpose of this 8-K filing is to officially report Regeneron Pharmaceuticals, Inc.'s financial and operating results for the third quarter ended September 30, 2009, through an attached press release.

The detailed financial and operational results are contained within the press release dated November 3, 2009, which is included as Exhibit 99.1 to this 8-K filing.

Investors should look for key financial metrics such as revenue, net income, earnings per share, and updates on the company's drug development pipeline, clinical trial progress, and any significant strategic announcements made during the third quarter of 2009.